Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new sedative keep seniors Clear-Headed after cancer surgery?

NCT ID NCT07351474

Symptom relief Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study tests whether remimazolam, a newer anesthetic, can reduce the risk of postoperative delirium (sudden confusion) in elderly patients undergoing laparoscopic stomach cancer surgery. Researchers will compare remimazolam to standard anesthesia in 170 patients aged 65 and older. The goal is to see if this drug leads to better recovery and fewer cognitive issues after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remimazolam
What this could lead to
If successful, this could point toward a safer anesthetic option for elderly patients, potentially reducing confusion and cognitive decline after major surgery.
What could go wrong
This is a small, early-stage trial (170 participants) that has not yet started recruiting. The results may not apply to all patients, and remimazolam may not prove better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

147 people

The number who actually took part.

Started

Jan 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 65 years. * Body mass index (BMI) between 18 and 28 kg/m². * ASA physical status I-III. * Scheduled for elective laparoscopic radical gastrectomy under general anesthesia at Jiangsu Province Hospital. * Able and willing to sign informed consent. Exclusion Criteria: * Severe respiratory, cardiovascular, renal, or hepatic dysfunction. * Stroke within the past 6 months or other central nervous system diseases. * History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or other psychiatric disorders. * History of alcohol abuse or psychoactive substance dependence. * Severe visual, hearing, or language impairment preventing communication. * Allergy or contraindication to propofol or benzodiazepines. * Preoperative cognitive impairment assessed by MMSE (≤24 for ≥middle-school education; ≤20 for primary school; ≤17 for no formal education). * Participation in another drug clinical trial within 1 month before surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Emergence Delirium gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Postoperative delirium

Contacts and locations

Locations

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.